NGL FINE-CHEM LIMITED

August 17, 2026

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai 400 001.

Scrip Code: 524774

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No.C/1, G Block,
Bandra Kurla Complex, Bandra East,
Mumbai 400051.

Symbol: NGLFINE

Dear Sir/Madam,

Sub: Investor Presentation – Q1FY 27.

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit **Investors Presentation – Q1FY 27**.

The above presentation is also being made available on the Company's website at www.nglfinechem.com.

You are requested to kindly take the information on record.
Thanking you,

Yours faithfully,
For NGL Fine-Chem Limited

Shivam Jagdish Gharat
Digitally signed by Shivam Jagdish Gharat
Date: 2026.08.17 14:42:07 +05'30'

Shivam Gharat
Company Secretary and Compliance Officer
M. No.: A56704

Encl: As Above.

Regd. Office
301, E Square, Subhash Road,
Vile Parle (East), Mumbai-
400057, Maharashtra, India

022-40842222
nglfinechem.com
info@nglfinechem.com
CIN: L24110MH1981PLC025884

NGL FINE-CHEM LIMITED

NGL Fine-Chem Limited

INVESTOR PRESENTATION

Q1FY27

Disclaimer

This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be deemed to constitute an offer. No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements", including those relating to the general business plans and strategy of NGL Fine-Chem Limited, its future financial condition and growth prospects, future developments in its industry and its competitive and regulatory environment, and statements which contain words or phrases such as 'will', 'expected to', 'horizons of growth', 'strong growth prospects', etc., or similar expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. NGL Fine-Chem Limited may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner.

Inside **This Presentation**

01

Q1FY27 **Highlights**



MANAGEMENT COMMENTARY

Rahul Nachane

MANAGING DIRECTOR

Dear Shareholders,

"Q1FY27 sustained the demand momentum we witnessed in Q4FY26, with volumes remaining robust across our product segments and geographies. The business continues on its recovery trajectory, supported by stable market conditions and improved customer off-take.

The quarter reflects healthy operating margins; however, part of the improvement is attributable to inventory gains arising from price increases during the period. As price realisations normalise, we expect margins to moderate over the coming quarters, which we view as a natural correction and not indicative of any structural change in the business. We continue to remain confident about our medium-term earnings outlook, driven by underlying demand and operating leverage.

A notable contributor to improved profitability this quarter was the reversal of mark-to-market forex provisions that had weighed on Q4FY26 results. Against a loss of ₹4.5 crore in Q4FY26, we recorded a forex gain of ₹2.5 crore in Q1FY27, providing a measurable uplift to reported earnings. Investors should note that these mark-to-market movements are inherently volatile and may not recur at the same magnitude in future periods.

On the capex front, Phase II remains on schedule and is expected to be commissioned during the current quarter. Total project cost and scope remain unchanged, and we are on track to commence commercial production from H2FY27 as planned. The incremental capacity is expected to support our growth plans and enhance our ability to address emerging opportunities in both existing and new markets.

With a stable market environment, sustained demand, and our expanded capacity, we believe the business is well-positioned to deliver steady, sustainable growth in the medium term."

Quarterly Operational Metrics

SEGMENTAL REVENUE MIX

PARTICULARS	Q1FY26	Q4FY26	Q1FY27
ANIMAL API	92%	95%	**95%**
HUMAN API	4%	2%	**3%**
INTERMEDIATES	3%	1%	**1%**
FORMULATIONS	1%	1%	**0%**

PRODUCT CONCENTRATION

PARTICULARS	Q1FY26	Q4FY26	Q1FY27
TOP 3 PRODUCTS	30%	29%	**31%**
TOP 5 PRODUCTS	42%	44%	**48%**
TOP 10 PRODUCTS	63%	66%	**68%**

GEOGRAPHIC MIX

PARTICULARS	Q1FY26	Q4FY26	Q1FY27
Asia	32%	43%	**40%**
Europe	13%	9%	**10%**
India	25%	23%	**20%**
ROW	30%	26%	**30%**
USA	1%	0%	**0%**

CUSTOMER CONCENTRATION

PARTICULARS	Q1FY26	Q4FY26	Q1FY27
TOP 3 CUSTOMERS	15%	12%	**18%**
TOP 5 CUSTOMERS	21%	18%	**26%**
TOP 10 CUSTOMERS	37%	29%	**38%**

Summary of Profit and Loss Statement

₹ IN CRORES

PARTICULARS	Q1FY26	Q4FY26	**Q1FY27**	Q-o-Q	Y-o-Y
REVENUE FROM OPERATIONS	104.19	149.23	139.16	-6.75%	33.57%
OTHER INCOME	6.35	2.46	7.43	202.05%	16.91%
TOTAL INCOME	**110.54**	**151.69**	**146.59**	**-3.36%**	**32.61%**
TOTAL OPERATING EXPENSES	93.21	127.82	115.88	-9.35%	24.31%
EBITDA	**10.97**	**21.41**	**23.29**	**8.76%**	**112.21%**
EBITDA MARGIN (%)	10.53%	14.35%	16.73%	239 bps	620 bps
FINANCE COST	1.22	1.01	0.99	-2.23%	-19.39%
DEPRECIATION AND AMORTISATION EXPENSES	4.27	5.05	5.25	4.01%	23.16%
PROFIT BEFORE TAX	11.84	17.81	24.48	37.41%	106.74%
PROFIT AFTER TAX	**9.24**	**13.49**	**18.40**	**36.42%**	**99.09%**

Summary of Balance Sheet

₹ IN CRORES

PARTICULARS	FY25	FY26
SHAREHOLDERS FUND	**282.43**	**329.23**
NON CURRENT LIABILITIES	31.99	66.25
LONG TERM BORROWINGS	25.34	**56.40**
CURRENT LIABILITIES	118.97	150.01
SHORT TERM BORROWINGS	48.00	**52.02**
TOTAL EQUITY AND LIABILITIES	**433.39**	**545.50**
NON CURRENT ASSETS	198.01	269.11
NET BLOCK	142.12	**164.09**
CURRENT ASSETS	235.38	276.39
INVENTORIES	51.27	**70.28**
TRADE RECEIVABLES	82.84	**130.88**
CASH & BANK BALANCES	4.97	**5.11**
TOTAL ASSETS	**433.39**	**545.50**

Summary of Cash Flow Statement

₹ IN CRORES

PARTICULARS	FY25	FY26
CASH FLOW FROM OPERATING ACTIVITIES	32.36	43.32
CASH FLOW FROM INVESTING ACTIVITIES	(69.68)	(70.59)
CASH FLOW FROM FINANCING ACTIVITIES	37.46	29.55
NET CASH FLOW	**0.14**	**2.27**
CASH AT THE BEGINNING OF YEAR	0.40	0.53
CASH AT THE END OF YEAR	**0.53**	**2.81**

02

Overview, **Strengths and Strategy**

Leading Animal Health Company

COMPREHENSIVE PRODUCT PORTFOLIO

- 45 APIs (43 Veterinary APIs, 2 Human APIs), 1 Intermediates and 11 finished dosage forms
- Best quality and value-driven pricing

MARKET LEADERSHIP IN VETERINARY API

- Market leadership in our top products
- Growing position in next 4 – taking market share from other players

MANUFACTURING EXCELLENCE

- 3 state of the art manufacturing facilities
- Strong R&D capabilities in custom synthesis

LARGE GLOBAL PRESENCE

- Strong presence across the globe with country-wise regulatory approvals
- Strong presence in unregulated markets

LONG STANDING CUSTOMER RELATIONSHIPS

- ~451 customers
- Reliable supplier focused on good sale support to all customers

Leadership in Veterinary API Segment

Strong controls of processes with **95%** in-house manufacturing and backward integrated facilities leading to cost competitiveness

High quality and reliable products with no market rejection in **15 years**

Market share ranging from **15% to 50%+** in key products

Suppliers to **5 of top 10** global animal healthcare companies

REVENUE FROM VETERINARY API SEGMENT
(₹ IN CRORES)

13% CAGR



WIDE RANGE OF PRODUCT CATEGORIES

- ANTHELMINTICS
- ECTOPARASITICIDES
- ANTIPROTOZOALS
- PHOSPHORUS SUPPLEMENTS

CUSTOMER & PRODUCT CONCENTRATION (OF SALES FY26)

	CUSTOMER	PRODUCT
TOP 3	10% (12% FY25)	28% (33% FY25)
TOP 5	15% (19% FY25)	45% (47% FY25)
TOP 10	26% (30% FY25)	65% (68% FY25)

State-of-the-art Manufacturing Capabilities

5 manufacturing facilities located at Tarapur & Navi Mumbai, Maharashtra, designed to meet the requirements of regulatory agencies and are capable of a wide range of reaction capabilities



PRODUCTION COMING FROM ZERO LIQUID DISCHARGE FACILITIES

HIGHLIGHTS

20,000 m^2
AREA OF MANUFACTURING FACILITIES

168 kl
GLASS-LINED REACTORS

253 kl
STAINLESS STEEL REACTORS

36 m^3
GAS INDUCTION REACTORS

-20°C to +250°C
REACTION RANGE

ACCREDITATIONS
WHO-GMP, ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and cGMP accredited

Strategy for next leg of growth

ONGOING INITIATIVES TO INCREASE CAPACITIES TO MEET GROWING DEMAND

BROWNFIELD EXPANSION

- Completed expansion in subsidiary Macrotech
- Additional capacities of intermediates
- Commercial production started

LARGER EXPANSION TO DRIVE THE NEXT LEG OF EXPONENTIAL GROWTH

GREENFIELD EXPANSION AT TARAPUR

- Capacity expansion with sufficient capacity to meet demand for new products in pipeline
- Estimated capex of ₹ 210 Cr to be funded through debt and internal accrual
- Civil construction undergoing. Invested ₹ 209.71 crores till Q1FY27

03

Historical Financial **Performance**

16 ROBUST FINANCIAL PERFORMANCE



Robust Financial Performance

REVENUE
(₹ IN CRORES)



EBITDA
(₹ IN CRORES)



PAT
(₹ IN CRORES)



GROSS MARGIN
(IN %)



EBITDA MARGIN
(IN %)



PAT MARGIN
(IN %)



EBITDA excludes Other Income

Thank **You**

nglfinechem.com

FOR ANY FURTHER INFORMATION, PLEASE CONTACT

Shivam Gharat
NGL FINE-CHEM LIMITED
cs@nglfinechem.com
+91 22 40842222

Abhishek Mehra
TIL ADVISORS PRIVATE LIMITED
abhishek@theinvestmentlab.in
+91 95588 14500

NGL FINE-CHEM LIMITED

Corporate Office
301, E-square, Subhash Road,
Vile Parle (East),
Mumbai - 400057,
Maharashtra, India